Professional and proven scientific advice from the initial development of a drug to the submission of a marketing-authorisation application and the post-authorisation phase.
Receive tailormade advice on the pros and cons of available options with special attention to current standards, regulations, and guidelines.
New Technology Assessment
IASON also identifies potential collaboration partners for strengthening your portfolio, understands and assesses technology platforms, and also assesses the suitability of a novel technology on your behalf.
Guidelines and guidance documents provide a good initial overview on drug and device development. Due to their generic nature, however, they rarely apply to real life product development plans. IASON consulting is happy to step in and assists you with proven advice where official documentation has left gaps.
Receive detailed feedback on your clinical development and scientific strategies as well as advice on which studies are necessary for small molecules, antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), antibody therapeutics or next generation biopharmaceuticals, vaccines, antiallergics, oncolytic viruses, biosimilars, homeopathic remedies, or herbal medicines.
Scientific advice is prospective in nature, focusing on development strategies rather than pre-evaluation of data to support a marketing-authorisation application. It helps to integrate cost-effectiveness considerations into your evidence generation plans.